COVID-19: Vaccines, pills, antibodies... What new treatments will be available in the coming weeks?

COVID-19: Vaccines, pills, antibodies… What new treatments will be available in the coming weeks?

primary
At the beginning of 2022, new treatments will be launched that will help fight Covid-19. Medicines, treatments, vaccines … La Dépêche du Midi evaluates new solutions on the market.

Omicron’s wave will be “the last with many limitations”. On Monday, January 17, Pfizer Laboratory CEO Albert Burla optimistically announced the change, and a possible return to “previous life” very soon. The goal: “coexist with viruses” by relying on “tools created by science,” according to the director. Not effective enough to prevent or treat serious forms of Covid-19, since the beginning of the health crisis two years ago, many drugs have been developed without convincing.

And now, this January, the scientific community is preparing to lift the veil on new products that could make it possible to fight SARS in the long-term against SARS-CoV-2. Medidispatch make a point.

Paxilvid, Pfizer’s pills

It is expected that the “Paxlovid” pill, developed by Pfizer, will arrive at the end of January in French pharmacies. Pfizer has developed a tablet similar in many respects to Monulpavir (an antiviral drug developed by the Merck Laboratory). According to the results of clinical trials published by the Pfizer laboratory, if drug therapy with Paxlovid is followed correctly within three days of onset of symptoms, it will reduce deaths and hospitalizations associated with Covid-19 by 89%.

Read also:
Covid-19: Efficacy and Marketing … Six Questions About Paxlovid, Pfizer’s Antiviral Pill

Practically speaking, for a patient with Covid-19, it would be a question of combining two pills, twice a day, for five days, to prevent serious forms of Covid-19.

Sotrovimab, a monoclonal antibody

They’ve come a long way since March 2021: Monoclonal antibody therapies are on the rise. According to the National Agency for the Safety of Medicines (ANSM), it is a matter of isolating an antibody in a person already infected with the Covid-19 virus, and reproducing it in large quantities in a laboratory. It is then re-injected by infusion into infected patients, in order to avoid dangerous forms of the virus.

Read also:
COVID-19: Two new treatments recommended by the World Health Organization in very specific cases

Several treatments have been tested but not all are effective against the Omicron variant. This is the case, among other things, of Bamlanivimab, or even Ronapreve, which was praised by the former President of the United States, Donald Trump. On the other hand, Xevudy (or sotrovimab) has proven itself: recommended by the World Health Organization. The structure recommends Xevudy for patients infected with the Covid virus who are at high risk of hospitalization. It will be available in France at the end of January.

Novavax Vaccine New Arrival

This is the fifth vaccine to be licensed in France: Novavax (designed by the American company of the same name) is based on the so-called “classic” technology. The technology it uses is not messenger RNA, as it adopts vaccines developed by Pfizer and Moderna, the most injected in France. It is, like childhood vaccines already widely used, the so-called “subunit” vaccine, which is based on proteins that trigger an immune response, without viruses.

Read also:
COVID-19: What we know about the Novavax vaccine that is supposed to arrive in February in France

Clinical trials of this new vaccine, involving 45,000 people in total, showed an efficacy of nearly 90% against symptomatic forms. On January 14, the Supreme Health Authority gave the green light to use it as a primary immunization for people aged 18 and over. The Health Ministry said the first deliveries of the Novavax vaccine (marketed as Novaxovid) are expected to take place in early February.

Leave a Comment

Your email address will not be published.